Sells design and trial software so deeply embedded in aerospace and drug regulations that customers cannot leave without destroying decades of approved work.
What this company is and how it runs — written from structure, not news.
Dassault Systèmes makes the software that Boeing and Airbus use to design aircraft and that pharmaceutical companies use to run clinical trials — and in both cases, the files those customers create are the legal record that regulators accept as proof the work was done correctly. In aerospace, four decades of Boeing and Airbus certification cycles have deposited their approved geometry inside CATIA's proprietary mathematical format, and because every future design change on an in-service aircraft must be computed by the same kernel that produced the original certified file, switching to a competitor would require recreating that entire legal history from scratch. In clinical trials, MEDIDATA's data format is embedded inside FDA drug submissions as the validated audit trail, so a pharmaceutical company that moves to a rival platform mid-study must revalidate its entire data chain from the point it switched — a process that can delay drug approval by years, which means every patient enrolled under MEDIDATA adds to the cost of ever leaving. The one thing that could unwind both businesses is the same in each case: a regulator mandating an open standard that fully converts the existing proprietary files into a neutral format any competitor could read, because that would hand custody of decades of accumulated compliance history to a public specification rather than to Dassault.
How does this company make money?
Customers pay annual subscription fees for seats on the 3DEXPERIENCE platform — a SOLIDWORKS Standard licence costs thousands of dollars per year, while a full CATIA aerospace configuration runs to tens of thousands. MEDIDATA charges pharmaceutical companies per patient per study, so revenue grows automatically as more patients are enrolled in more trials. The company also earns fees for consulting services that help aerospace customers navigate certification workflows.
What makes this company hard to replace?
Aerospace customers would have to recreate from scratch every certified aircraft component geometry that currently exists only inside CATIA's proprietary mathematical format — there is no export path that preserves the legal validity of those files. Pharmaceutical companies that switch away from MEDIDATA mid-study must revalidate their entire data chain from the point of migration, a process that can push drug approval back by years. Manufacturing customers would need to manually reprogram every factory robot currently running on DELMIA-generated control code.
What limits this company?
The surface continuity calculations inside CATIA's kernel must run in a specific order — the same order used when the original certified files were created. Splitting that work across standard cloud infrastructure would change the computational sequence, which would trigger recertification obligations for every Boeing and Airbus programme currently using those files. That constraint means the platform cannot absorb modern cloud-speed improvements without risking the legal validity of the files its customers depend on.
What does this company depend on?
The company cannot run without Boeing and Airbus continuing to use CATIA-format certification workflows, Microsoft Azure hosting the 3DEXPERIENCE platform, NVIDIA GPU clusters powering SIMULIA's fluid dynamics calculations, pharmaceutical regulatory submission systems that accept MEDIDATA clinical trial data formats, and automotive OEM integration standards that connect ENOVIA to manufacturer data systems.
Who depends on this company?
Boeing and Airbus would lose the ability to modify any existing aircraft design stored in CATIA format — decades of certified geometry would become untouchable. Pharmaceutical companies running FDA clinical trials would lose the MEDIDATA-validated data chains the agency requires for drug approvals, potentially halting submissions already in progress. Automotive manufacturers would lose the DELMIA-generated control code that tells factory floor robots how to move, which would disrupt production automation.
How does this company scale?
Once CATIA's geometric modeling algorithms and MEDIDATA's clinical trial templates are built, they can be copied to unlimited additional users at almost no extra cost. What does not scale cheaply is the engineering talent needed to advance aerospace-grade surface continuity mathematics and the pharmaceutical regulatory expertise needed to keep MEDIDATA compliant — both require rare domain knowledge that money alone cannot quickly produce.
What external forces can significantly affect this company?
European data sovereignty rules require French companies to keep data processing for aerospace and pharmaceutical clients inside the EU, which shapes how the 3DEXPERIENCE platform can be hosted. U.S. export controls restrict which Chinese aerospace companies can access CATIA at all. On the demand side, an aging global population is pushing pharmaceutical companies to expand R&D, which increases the number of clinical trials running on MEDIDATA.
Where is this company structurally vulnerable?
If Boeing, Airbus, and their regulators jointly required an open geometric-exchange standard that converted existing CATIA-format files into a public specification with full fidelity, any well-funded software maker could implement that standard and legally access four decades of certified aircraft geometry. That single regulatory action would be the only thing capable of dissolving the file-format lock, because it would take custody of the certified design history away from CATIA's proprietary kernel and hand it to a public format anyone could read and write.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three multi-year observations co-occur: cash and equivalents increased year-over-year in each of the last four fiscal years, free cash flow was positive in each of the last three years, and long-term debt decreased year-over-year in each of the last three years. The configuration describes simultaneous multi-year consistency in cash accumulation, FCF generation, and LT-debt reduction.
Three observations co-occur: long-term debt decreased year-over-year in each of the last four fiscal years, total cash at MRQ is at least equal to total debt, and the industry-benchmarked equity ratio is in its elevated range. The configuration describes past LT-debt reduction consistency alongside cash-vs-debt position and equity-heavy capital structure.
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph